BioVaxys Technology (FRA:5LB0) Total Liabilities: €3.15 Mil (As of Jul. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioVaxys Technology Total Liabilities?

BioVaxys Technology FRA:5LB0 Total Liabilities is €3.15 Mil as of Jul. 2025.

BioVaxys Technology's Total Liabilities for the quarter that ended in Jul. 2025 was €3.15 Mil.

BioVaxys Technology's quarterly Total Liabilities increased from Jan. 2025 (€2.03 Mil) to Apr. 2025 (€2.44 Mil) and increased from Apr. 2025 (€2.44 Mil) to Jul. 2025 (€3.15 Mil).

BioVaxys Technology's annual Total Liabilities increased from Oct. 2022 (€1.22 Mil) to Oct. 2023 (€2.41 Mil) but then declined from Oct. 2023 (€2.41 Mil) to Oct. 2024 (€2.15 Mil).

BioVaxys Technology Total Liabilities Historical Data

* Premium members only.

The historical data trend for BioVaxys Technology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVaxys Technology Total Liabilities Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Total Liabilities
Get a 7-Day Free Trial 0.58 0.23 1.22 2.41 2.15

BioVaxys Technology Quarterly Data
Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.79 2.15 2.03 2.44 3.15

BioVaxys Technology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BioVaxys Technology's Total Liabilities for the fiscal year that ended in Oct. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.149+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.15

Total Liabilities=Total Assets (A: Oct. 2024 )-Total Equity (A: Oct. 2024 )
=0.868--1.281
=2.15

BioVaxys Technology's Total Liabilities for the quarter that ended in Jul. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.147+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=3.15

Total Liabilities=Total Assets (Q: Jul. 2025 )-Total Equity (Q: Jul. 2025 )
=0.868--2.279
=3.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €3.15 Mil mean?
BioVaxys Technology (FRA:5LB0) has a Total Liabilities of €3.15 Mil as of Jul. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for BioVaxys Technology and its competitors.
Is BioVaxys Technology's Total Liabilities too high?
BioVaxys Technology's current Total Liabilities is €3.15 Mil.
How does BioVaxys Technology's Total Liabilities compare to BPTH and AZTR?
BioVaxys Technology's Total Liabilities of €3.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for BioVaxys Technology and its competitors. BioVaxys Technology's current Total Liabilities is €3.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVaxys Technology stock overvalued right now?
BioVaxys Technology (FRA:5LB0) has a current Total Liabilities of €3.15 Mil. The current Total Liabilities is €3.15 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For BioVaxys Technology (FRA:5LB0), the current Total Liabilities is €3.15 Mil as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVaxys Technology Business Description

Other Exchanges BVAXF:USABIOV:Canada
Address 595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.